Ind-Swift Laboratories is currently trading at Rs. 50.60, up by 0.50 points or 1.00% from its previous closing of Rs. 50.10 on the BSE.
The scrip opened at Rs. 50.95 and has touched a high and low of Rs. 51.40 and Rs. 50.60 respectively. So far 3682 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 133.00 on 08-Feb-2012 and a 52 week low of Rs. 39.10 on 14-Aug-2012.
Last one week high and low of the scrip stood at Rs. 52.60 and Rs. 48.30 respectively. The current market cap of the company is Rs. 201.85 crore.
The promoters holding in the company stood at 50.58% while Institutions and Non-Institutions held 4.20% and 45.16% respectively.
Drug firm Ind-Swift Laboratories is targeting to garner revenues of Rs 1,500 crore by 2015. For achieving the same, the company will continue to focus on its active pharmaceuticals Ingredients (API) business in European Union, Japan, Australia and US which will be the main drivers of growth for future. At present, the company’s revenues stand at over Rs 1,000 crore.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API). The company’s business model is focused on domestic market and high-value mature regulated markets along with considerable focus on the emerging markets as well.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1522.40 |
Dr. Reddys Lab | 6405.75 |
Cipla | 1482.00 |
Zydus Lifesciences | 1074.35 |
Lupin | 1625.00 |
View more.. |